Drug
Muromonab-CD3 clinical trials
Also written OKT3.
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 9
Mayo Clinic (2) · Hadassah Medical Organization (2) · St. Anna Kinderkrebsforschung (2) · St. Jude Children's Research Hospital (1) · Brigham and Women's Hospital (1) · Fred Hutchinson Cancer Center (1)
Often tested with
Tested in the same studies.
Fludarabine (4) · Thiotepa (4) · Cyclosporine (2) · Etoposide (2) · Antilymphocyte Serum (2) · Treosulfan (2) · Melphalan (1) · Mycophenolic Acid (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunologic Factors source
- One of Immunosuppressive Agents source
Studies
Open first, then newest update. How each study uses Muromonab-CD3 is read from its arms, and is right about nine times in ten.
Testing it · 9
- Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedPhase 2St. Jude Children's Research HospitalNCT00566696Written as Muromonab
- Oral OKT3 for the Treatment of Active Ulcerative ColitisCompletedPhase 1/2Brigham and Women's HospitalNCT01287195Written as Oral OKT3
- Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood DiseasesTerminatedPhase 2Fred Hutchinson Cancer CenterNCT00450983Written as muromonab-CD3
- ALL-SCT BFM International- HSCT in Children and Adolescents With ALLStatus unknownPhase 3St. Anna KinderkrebsforschungNCT01423500Written as Fludarabine, OKT3, Treosulfan, Thiotepa
- Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic LeukaemiaStatus unknownPhase 3St. Anna KinderkrebsforschungNCT01423747Written as Fludarabine, OKT3, Treosulfan, Thiotepa
- Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell MyocarditisCompletedNot applicableMayo ClinicNCT00027443Written as Muromonab-CD3
- Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic SyndromeCompletedPhase 2Hadassah Medical OrganizationNCT01205087Written as OKT3
- Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell MyocarditisCompletedPhase 2Mayo ClinicNCT00004482Written as Muromonab-CD3
- Oral OKT3 in Combination With Beta-D-GlucosylceramideStatus unknownPhase 1Hadassah Medical OrganizationNCT00619372Written as OKT3
Codes
What other systems call Muromonab-CD3 · ClinicalTrials.gg INT008548
- MeSH (NLM) D016853Muromonab-CD3Confirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) JGA39ICE2VMUROMONAB-CD3Confirmed FDA, Wikidata
- RxNorm 42405Confirmed FDA, Wikidata
- Wikidata Q416494muromonabConfirmed FDA, Wikidata
- NCI Thesaurus C1321Muromonab-CD3One source FDA
- DrugBank DB00075One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D016853 | Muromonab-CD3 | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | JGA39ICE2V | MUROMONAB-CD3 | Confirmed FDA, Wikidata |
| RxNorm | 42405 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416494 | muromonab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C1321 | Muromonab-CD3 | One source FDA |
| DrugBank | DB00075 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.